ICON plc, globally the fifth-largest clinical research organization, announced its acquisition of Beijing KendleWits Medical Consulting Co., Ltd., a CRO in China. ICON entered the Chinese CRO market in 2005 and currently employs a staff of 60. KendleWits’s general manager Xie Yan said that the deal can help ICON quickly enter China’s clinical trial market by means of KendleWits’ international standard quality and a wealth of experience in conducting clinical activities throughout the country. She added that KendleWit is expected to become ICON’s main force in China. (Click Here For More - Chinese Language
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?